Abivax SA Stock News

Abivax Presents Business Updates and First Half 2026 Financial Results  Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax's Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions Cash, cash equivalents and short-term investments of €402.4 m...

Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under intense scrutiny as an acquisition target by a larger peer.

Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory di...

Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Abivax SA raised $800 million in an ​expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 ‌billion and easing pressure to pursue a near-term sale.

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammat...